Milrinone LactateThird Party Manufacturing in India

Milrinone Lactate works by selectively inhibiting the enzyme phosphodiesterase 3 (PDE3) in cardiac and vascular smooth muscle tissue.

By blocking PDE3, it prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated intracellular cAMP levels. In the heart, this increases calcium influx, enhancing myocardial contractility (a positive inotropic effect). In the vascular system, it promotes smooth muscle relaxation, causing systemic and pulmonary vasodilation.

Unlike beta-adrenergic agonists, Milrinone Lactate exerts its effects without relying on beta receptors. It is highly effective for patients requiring short-term hemodynamic support for acute decompensated heart failure.

Therapeutic Uses

Milrinone Lactate is prescribed for the treatment of:

• Acute Heart Failure: Provides short-term intravenous therapy for patients with acute decompensated heart failure.
• Post-Cardiac Surgery: Used for inotropic support in patients recovering from cardiac surgical procedures.
• Pulmonary Hypertension: Assists in managing elevated pulmonary vascular resistance in critical care settings.

Why Manufacturers Choose Milrinone Lactate

Milrinone Lactate is a specialized critical-care cardiovascular drug that requires advanced sterile manufacturing capabilities. It has strong continuous demand from cardiac centers and intensive care units globally.

This makes Milrinone Lactate a highly sought-after molecule for third party manufacturing in India, with consistent demand from institutional buyers, specialized franchise operators, and export-oriented companies.